FDA update on brand drugs for January 14, 2010

[chantell.reagan]

Actemra (tocilizumab) IV infusion by Genentech
Approval: an interleukin-6 (IL-6) receptor inhibitor indicated for treatment of adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies

•Link to Genentech press release 1/10
•Link to Actemra REMS program
•Link to prescribing information

Sources:

U.S. Food and Drug Administration. Drugs@FDA. Available at: Drugs@FDA
U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. Available at: CBER